Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Quality Of Life in Prostate Cancer Patients Initiating Triptorelin (QOCPIT)

16. november 2026 oppdatert av: Ipsen

QOCPIT (Quality Of Life in Prostate Cancer Patients Initiating Triptorelin): A Prospective Observational Study to Evaluate Baseline Factors That Stabilize or Improve Health-related Quality of Life.

Prostate cancer and its treatment, particularly androgen deprivation therapy (ADT) may affect different aspects of a person's quality of life, including physical well-being and daily activities.

The purpose of this study is to evaluate baseline factors that stabilize or improve quality of life in patients with prostate cancer who are initiating triptorelin treatment as ADT, in routine clinical practice.

Participants in this study will be patients with prostate cancer whose treating physician has decided to initiate treatment with triptorelin.

This is an observational study. No treatment will be assigned as part of the study, and all medical decisions will be made by the treating physician according to routine clinical practice.

Participants will be followed for approximately 6 months. Information collected during the study may include demographics and medical characteristics, prostate cancer and treatments characteristics, physical activity, supportive care and quality of life. Questionnaires about quality of life and physical activity will be completed by participants at the start of the study and again approximately 6 months later. Information on adverse events occurring during the study will also be collected.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Studietype

Observasjonsmessig

Registrering (Antatt)

819

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Mann

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adult males with prostate cancer initiating triptorelin treatment in routine clinical practice and meeting the study eligibility criteria.

Beskrivelse

Inclusion Criteria:

Patients are eligible to be included in the study only if all the following criteria apply:

  1. Males ≥18 years old.
  2. Patient with histologically confirmed PCa.
  3. Patient eligible to start triptorelin in its labelled indication for at least 6 months and for whom the decision to start triptorelin was made voluntarily by the physician as part of routine medical practice, prior to the inclusion in the study.
  4. Patient able to understand and complete study-related questionnaires.
  5. Patient having been informed and not opposed to participating in the study.
  6. Patient covered by healthcare insurance.

Exclusion Criteria

Patients will not be included in the study if they meet any of the following criteria:

  1. Patient currently participating in any interventional clinical trial.
  2. Patient who received a hormonal treatment during the last 6 months before inclusion (or hormonal treatment whose duration of action may impact the 6 months before inclusion).
  3. Patient under tutorship or curatorship; patients under safeguard of justice or deprived of his liberty by an administrative or court decision.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Identification of baseline factors including: demographic, clinical, disease and treatment factors, associated with stabilization (change:]-10; 10[) or improvement (change ≥10) of Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score
Tidsramme: At 6 months
At 6 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Participants' baseline demographic characteristics
Tidsramme: At baseline

Including:

  • Age.
  • Partnership status.
  • Employment status.
  • Area of residence.
  • Socioeconomic status.
At baseline
Participants' clinical characteristics at baseline
Tidsramme: At baseline

Including:

  • BMI
  • Eastern Cooperative Oncology Group (ECOG) Performance status score.
  • G8 score if applicable.
  • Comorbidity status, medical and surgical history, and systemic treatments for comorbidities.
  • Participant's level of physical activity, using IPAQ questionnaire.
At baseline
Prostate cancer characteristics at diagnosis and baseline
Tidsramme: At baseline

Including:

  • Prostate Cancer (PCa) presentation (new diagnosis or recurrence/progression) at baseline.
  • Gleason score/International Society of Urological Pathology (ISUP) group
  • TNM (Tumor Node Metastasis) at diagnosis.
  • Prostate Specific Antigen (PSA) and testosterone levels at PCa diagnosis.
  • Previous treatments received for PCa, if any.
At baseline
Participants symptoms at baseline
Tidsramme: At baseline
At baseline
Participants' PCa treatment patterns at baseline
Tidsramme: At baseline
  • Triptorelin treatment modalities
  • Radiotherapy modalities
  • Associated systemic PCa treatments
At baseline
Participants' healthcare pathway/supportive care done or planned
Tidsramme: At baseline

Including:

  • Pretreatment assessments
  • Visits to supportive health care professionals done or planned.
  • Participation in a dedicated healthcare pathway (as a one-day hospital stay with visits to several healthcare professionals).
  • Associated prescriptions or recommendations
  • Complementary information on cancer patient organizations and/or websites.
At baseline
Evolution of PCa at 6-month follow-up according to investigator's opinion
Tidsramme: At 6 months

Evolution of PCa at 6-month follow-up according to investigator's opinion: control / stable / progression.

At 6 months
Symptoms and biological characteristics at 6 months
Tidsramme: At 6 months
At 6 months
Participant's level of physical activity, using International Physical Activity Questionnaire (IPAQ) questionnaire
Tidsramme: At 6 months

The International Physical Activity Questionnaire (IPAQ) is a participant-reported questionnaire used to assess physical activity level. Higher scores indicate higher levels of physical activity.

At 6 months
Participants' Quality Of life (QoL)
Tidsramme: At baseline and at 6 months
  • FACT-P total score, sub-scores and individual items, at baseline and at 6- month follow-up, and their changes from baseline.
  • European Organisation for Research and Treatment of CancerQuality-of-Life Questionnaire Prostate Module (EORTC QLQ-PR25) sexual activity individual items and domain scores at baseline and at 6-month follow-up and changes from baseline.
At baseline and at 6 months
Participants' PCa treatment patterns at 6 months
Tidsramme: At baseline and at 6 months
  • Collection of triptorelin administrations from initiation
  • Radiotherapy modalities in case of changes,
  • Associated systemic PCa treatments in case of changes.
At baseline and at 6 months
Participants' healthcare pathway/supportive care at 6 months
Tidsramme: At 6 months

• Participant's healthcare pathway/type of supportive care in case of changes.

At 6 months
Identification of factors associated with participant's quality of life
Tidsramme: At 6 months

• Identification of baseline factors, including demographic, clinical, disease and treatment factors, associated with stabilization (change: ]-3;3[) or improvement (change ≥3) of Physical Well-Being (PWB) and Prostate Cancer Specific (PCS) sub-scores of FACT-P at 6 months after inclusion, using a logistic model.

At 6 months
Percentage of participants with adverse events
Tidsramme: From enrollment to Month 6

An adverse event (AE) is any untoward medical occurrence in a participant. The percentage of participants experiencing at least one adverse event, including cardiovascular events occurring after initiation of triptorelin treatment, will be assessed during study follow-up.

From enrollment to Month 6

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Ipsen Medical Director, Ipsen

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

23. november 2026

Primær fullføring (Antatt)

25. februar 2028

Studiet fullført (Antatt)

30. oktober 2028

Datoer for studieregistrering

Først innsendt

16. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

IPD-delingstidsramme

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Tilgangskriterier for IPD-deling

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere